Non-Small Cell Lung Cancer - Pipeline Review, H2 2016

Date: December 28, 2016
Pages: 2236
Price:
US$ 2,500.00 US$ 2,000.00
Offer valid until June 2, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NA28E2E58C0EN
Leaflet:

Download PDF Leaflet

Non-Small Cell Lung Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer – Pipeline Review, H2 2016, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 45, 178, 148, 1, 16, 156, 17 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 7, 37 and 7 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Non-Small Cell Lung Cancer Overview
Therapeutics Development
Non-Small Cell Lung Cancer - Therapeutics under Development by Companies
Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes
Non-Small Cell Lung Cancer - Pipeline Products Glance
Non-Small Cell Lung Cancer - Products under Development by Companies
Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development
Non-Small Cell Lung Cancer - Therapeutics Assessment
Drug Profiles
Non-Small Cell Lung Cancer - Dormant Projects 2104
Non-Small Cell Lung Cancer - Discontinued Products 2139
Non-Small Cell Lung Cancer - Product Development Milestones 2153
Appendix 2169

LIST OF TABLES

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2016
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Development by Companies, H2 2016 (Contd..11)
Number of Products under Development by Companies, H2 2016 (Contd..12)
Number of Products under Development by Companies, H2 2016 (Contd..13)
Number of Products under Development by Companies, H2 2016 (Contd..14)
Number of Products under Development by Companies, H2 2016 (Contd..15)
Number of Products under Development by Companies, H2 2016 (Contd..16)
Number of Products under Development by Companies, H2 2016 (Contd..17)
Number of Products under Development by Companies, H2 2016 (Contd..18)
Number of Products under Development by Companies, H2 2016 (Contd..19)
Number of Products under Development by Companies, H2 2016 (Contd..20)
Number of Products under Development by Companies, H2 2016 (Contd..21)
Number of Products under Development by Companies, H2 2016 (Contd..22)
Number of Products under Development by Companies, H2 2016 (Contd..23)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Development by Companies, H2 2016 (Contd..17)
Products under Development by Companies, H2 2016 (Contd..18)
Products under Development by Companies, H2 2016 (Contd..19)
Products under Development by Companies, H2 2016 (Contd..20)
Products under Development by Companies, H2 2016 (Contd..21)
Products under Development by Companies, H2 2016 (Contd..22)
Products under Development by Companies, H2 2016 (Contd..23)
Products under Development by Companies, H2 2016 (Contd..24)
Products under Development by Companies, H2 2016 (Contd..25)
Products under Development by Companies, H2 2016 (Contd..26)
Products under Development by Companies, H2 2016 (Contd..27)
Products under Development by Companies, H2 2016 (Contd..28)
Products under Development by Companies, H2 2016 (Contd..29)
Products under Development by Companies, H2 2016 (Contd..30)
Products under Development by Companies, H2 2016 (Contd..31)
Products under Development by Companies, H2 2016 (Contd..32)
Products under Development by Companies, H2 2016 (Contd..33)
Products under Development by Companies, H2 2016 (Contd..34)
Products under Development by Companies, H2 2016 (Contd..35)
Products under Development by Companies, H2 2016 (Contd..36)
Products under Development by Companies, H2 2016 (Contd..37)
Products under Development by Companies, H2 2016 (Contd..38)
Products under Development by Companies, H2 2016 (Contd..39)
Products under Development by Companies, H2 2016 (Contd..40)
Products under Development by Companies, H2 2016 (Contd..41)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H2 2016
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2016
Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Almac Discovery Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by APO-T BV, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Arog Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Axelar AB, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2016
Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by BerGenBio AS, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Biocad, H2 2016
Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by CanBas Co Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H2 2016
Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Celgene Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Cellceutix Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Cellmid Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Cielo Therapeutics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Cipla Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Cleave Biosciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
Non-Small Cell Lung Cancer - Pipeline by CTI BioPharma Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by CytImmune Sciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by CytRx Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H2 2016
Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma LLC, H2 2016
Non-Small Cell Lung Cancer - Pipeline by DiNonA Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Domainex Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by DormaTarg Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by EirGenix Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Eisai Co Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Endocyte Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by EntreChem SL, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Enumeral Biomedical Holdings Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Eudendron Srl, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Evotec AG, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Exelixis Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by FibroStatin SL, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Fujifilm Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Genelux Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Genentech Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Genmab A/S, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Genocea Biosciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Genosco Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Globeimmune Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Glycotope GmbH, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Gradalis Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Grunenthal GmbH, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Heat Biologics Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by HEC Pharm Co Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Heptares Therapeutics Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by HitGen LTD, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by iCeutica Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Ignyta Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by ImmunGene Inc, H2 2016
Non-Small Cell Lung Cancer - Pipeline by Immunocore Ltd, H2 2016
Non-Small Cell Lung Cancer - Pipeline by ImmunoGen Inc, H2 2016 311

LIST OF FIGURES

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2016
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ask Your Question

Non-Small Cell Lung Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: